All In Biotech

Drug Trial Radar · NCT04699669

A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers

A 2-stage, Phase 1/2a Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat (Phase 1)

Last checked: Nov 19, 2026Latest source record: Jan 7, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Nov 27, 2018

Primary completion

Aug 20, 2019

Study completion Aug 20, 2019

Sponsor

Sponsor type
Industry
First posted
Jan 7, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The Phase 1 component of the study is a double-blind, placebo-controlled, single ascending dose (SAD) design intended to assess the safety, tolerability, and PK of CBL-514. The SAD part will involve 9 proposed dosing cohorts.

Conditions

  • Subcutaneous Fat

Interventions

  • CBL-514, placeboDrug

    One side of the abdominal region will receive CBL-514, while the other will receive placebo with equal volume. Which side of the abdominal region to receive CBL-514 or placebo would be randomized. No PK samples will be collected in this cohort.

  • CBL-514, placeboDrug

    One side of the abdominal region will receive CBL-514, while the other will receive placebo with equal volume. Which side of the abdominal region to receive CBL-514 or placebo would be randomized.

  • CBL-514Drug

    Both sides of the abdominal region will receive CBL-514.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment emergent adverse events (TEAEs)Time frame: Up to 4 weeks after treatment
  2. Number of participants with clinically significant abnormalities in clinical laboratory valuesTime frame: Up to 2 weeks after treatment
  3. Number of participants with clinically significant abnormalities in vital signsTime frame: Up to 2 weeks after treatment
  4. Number of participants with clinically significant abnormalities in Electrocardiogram (ECG)Time frame: Up to 2 weeks after treatment
  5. Number of participants with clinically significant abnormalities in physical examinationTime frame: Up to 2 weeks after treatment
  6. Number of participants with injection site reactionsTime frame: Up to 2 weeks after treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Investigational site

    Melbourne, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.